Novartis shares fell sharply following the failure of its late-stage drug candidates pelacarsen and del-desiran in phase 3 trials, which impacts the company’s near-term growth prospects. Despite these setbacks, Novartis reaffirmed its revenue growth guidance of 5-6% CAGR for 2025-2030, supported by the successful phase 3 results of Rhapsido for relapsing multiple sclerosis, which could generate over $3 billion in annual peak sales. The company’s long-term position in the market remains strong, though near-term share price gains may be limited due to the recent trial failures and lack of other catalysts.
Novartis announced that its drug pelacarsen, designed to lower the harmful cholesterol Lp(a), failed to significantly reduce cardiovascular events in a late-stage trial. This setback raises doubts about the effectiveness of targeting Lp(a) to prevent...
RBC Capital Markets reaffirmed its 'outperform' rating on Oxford BioMedica, despite clinical trial pauses by partners Novartis and BMS. The broker views the trial halts as having limited financial impact, with only £10-16 million in annual clinical r...
Novartis has agreed to pay up to $3 billion to license Alteogen's Hybrozyme platform, which uses an enzyme to allow large biologic drugs to be absorbed faster via subcutaneous injections instead of long intravenous infusions. This innovation could im...
